Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C24H26N2O4.H3O4P |
| Molecular Weight | 504.4694 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OP(O)(O)=O.COC1=C(OCCNCC(O)COC2=CC=CC3=C2C4=C(N3)C=CC=C4)C=CC=C1
InChI
InChIKey=XCPXNPBILMXKNX-UHFFFAOYSA-N
InChI=1S/C24H26N2O4.H3O4P/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;1-5(2,3)4/h2-12,17,25-27H,13-16H2,1H3;(H3,1,2,3,4)
| Molecular Formula | C24H26N2O4 |
| Molecular Weight | 406.4742 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | H3O4P |
| Molecular Weight | 97.9952 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Carvedilol competitively blocks β1, β2 and α1 receptors. The drug lacks sympathomimetic activity and has vasodilating properties that are exerted primarily through α1-blockade. Animal models indicate that carvedilol confers protection against myocardial necrosis, arrhythmia and cell damage caused by oxidising free radicals, and the drug has no adverse effects on plasma lipid profiles. COREG® (carvedilol) is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. Carvedilol is the first drug of its kind to be approved for the treatment of congestive heart failure, and is now the standard of care for this devastating disease. Carvedilol is also confirmed as effective in the management of mild to moderate hypertension and ischaemic heart disease.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094118 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | COREG Approved UseCOREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization.
COREG is indicated to reduce cardiovascular mortality in clinically stable patients who
have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure).
COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Launch Date1995 |
|||
| Primary | COREG Approved UseCOREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization.
COREG is indicated to reduce cardiovascular mortality in clinically stable patients who
have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure).
COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Launch Date1995 |
|||
| Primary | COREG Approved UseCOREG® (carvedilol) is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization.
COREG is indicated to reduce cardiovascular mortality in clinically stable patients who
have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure).
COREG is indicated for the management of essential hypertension. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Launch Date1995 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
18.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10934668 |
6.25 mg 2 times / day steady-state, oral dose: 6.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CARVEDILOL, (+)- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
8.46 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10934668 |
6.25 mg 2 times / day steady-state, oral dose: 6.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CARVEDILOL, (-)- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
26.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10934668 |
6.25 mg 2 times / day steady-state, oral dose: 6.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CARVEDILOL plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
94.3 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10934668 |
6.25 mg 2 times / day steady-state, oral dose: 6.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CARVEDILOL, (+)- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
42.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10934668 |
6.25 mg 2 times / day steady-state, oral dose: 6.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CARVEDILOL, (-)- plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
139 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10934668 |
6.25 mg 2 times / day steady-state, oral dose: 6.25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CARVEDILOL plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Co-administed with:: lorazepam(7 mg) Sources: |
unknown, 41 years n = 1 Health Status: unknown Age Group: 41 years Sex: M Population Size: 1 Sources: |
Other AEs: Wheezing... |
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy, 66.7±12.0 years n = 7 Health Status: unhealthy Condition: chronic heart failure Age Group: 66.7±12.0 years Sex: M+F Population Size: 7 Sources: |
|
375 mg single, oral Overdose Dose: 375 mg Route: oral Route: single Dose: 375 mg Co-administed with:: simvastatin(fifteen 20-mg tablets) Sources: |
unhealthy, 84 years n = 1 Health Status: unhealthy Age Group: 84 years Sex: M Population Size: 1 Sources: |
Other AEs: Hypotension... |
50 mg 1 times / day steady, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy, adult n = 765 Health Status: unhealthy Condition: heart failure Age Group: adult Population Size: 765 Sources: |
Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension (0.7%) Sources: |
20 mg 2 times / day multiple, oral Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: p. 61 |
unhealthy, adult n = 54 Health Status: unhealthy Age Group: adult Population Size: 54 Sources: Page: p. 61 |
Disc. AE: Congestive cardiac failure... AEs leading to discontinuation/dose reduction: Congestive cardiac failure (moderate, 1 patient) Sources: Page: p. 61 |
25 mg 2 times / day steady, oral Dose: 25 mg, 2 times / day Route: oral Route: steady Dose: 25 mg, 2 times / day Sources: |
unhealthy, adult n = 1156 Health Status: unhealthy Condition: severe heart failure Age Group: adult Population Size: 1156 Sources: |
Disc. AE: Dizziness... AEs leading to discontinuation/dose reduction: Dizziness (1.3%) Sources: |
6.25 mg 2 times / day multiple, oral Dose: 6.25 mg, 2 times / day Route: oral Route: multiple Dose: 6.25 mg, 2 times / day Sources: Page: p. 61 |
unhealthy, adult n = 54 Health Status: unhealthy Age Group: adult Population Size: 54 Sources: Page: p. 61 |
Disc. AE: Abdominal distension... AEs leading to discontinuation/dose reduction: Abdominal distension (1 patient) Sources: Page: p. 61 |
6.25 mg 2 times / day multiple, oral Dose: 6.25 mg, 2 times / day Route: oral Route: multiple Dose: 6.25 mg, 2 times / day Sources: Page: p. 61 |
unhealthy, adult n = 54 Health Status: unhealthy Age Group: adult Population Size: 54 Sources: Page: p. 61 |
Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (moderate, 1 patient) Sources: Page: p. 61 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Wheezing | 1 patient | 300 mg single, oral Overdose Dose: 300 mg Route: oral Route: single Dose: 300 mg Co-administed with:: lorazepam(7 mg) Sources: |
unknown, 41 years n = 1 Health Status: unknown Age Group: 41 years Sex: M Population Size: 1 Sources: |
| Hypotension | 1 patient | 375 mg single, oral Overdose Dose: 375 mg Route: oral Route: single Dose: 375 mg Co-administed with:: simvastatin(fifteen 20-mg tablets) Sources: |
unhealthy, 84 years n = 1 Health Status: unhealthy Age Group: 84 years Sex: M Population Size: 1 Sources: |
| Hypotension | 0.7% Disc. AE |
50 mg 1 times / day steady, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: steady Dose: 50 mg, 1 times / day Sources: |
unhealthy, adult n = 765 Health Status: unhealthy Condition: heart failure Age Group: adult Population Size: 765 Sources: |
| Congestive cardiac failure | moderate, 1 patient Disc. AE |
20 mg 2 times / day multiple, oral Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: p. 61 |
unhealthy, adult n = 54 Health Status: unhealthy Age Group: adult Population Size: 54 Sources: Page: p. 61 |
| Dizziness | 1.3% Disc. AE |
25 mg 2 times / day steady, oral Dose: 25 mg, 2 times / day Route: oral Route: steady Dose: 25 mg, 2 times / day Sources: |
unhealthy, adult n = 1156 Health Status: unhealthy Condition: severe heart failure Age Group: adult Population Size: 1156 Sources: |
| Abdominal distension | 1 patient Disc. AE |
6.25 mg 2 times / day multiple, oral Dose: 6.25 mg, 2 times / day Route: oral Route: multiple Dose: 6.25 mg, 2 times / day Sources: Page: p. 61 |
unhealthy, adult n = 54 Health Status: unhealthy Age Group: adult Population Size: 54 Sources: Page: p. 61 |
| Rash | moderate, 1 patient Disc. AE |
6.25 mg 2 times / day multiple, oral Dose: 6.25 mg, 2 times / day Route: oral Route: multiple Dose: 6.25 mg, 2 times / day Sources: Page: p. 61 |
unhealthy, adult n = 54 Health Status: unhealthy Age Group: adult Population Size: 54 Sources: Page: p. 61 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Levosimendan. | 2001 |
|
| [Comparison of carvedilol and atenolol efficacy in patients with stable effort angina]. | 2001 |
|
| Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium. | 2001 Apr |
|
| Carvedilol--a new dimension in pediatric heart failure therapy. | 2001 Apr |
|
| 50th Annual scientific sessions of the American college of cardiology. | 2001 Apr 10 |
|
| Reducing readmissions for congestive heart failure. | 2001 Apr 15 |
|
| Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. | 2001 Feb |
|
| Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. | 2001 Feb 27 |
|
| Detection of low levels of the amorphous phase in crystalline pharmaceutical materials by thermally stimulated current spectrometry. | 2001 Jan |
|
| A placebo controlled evaluation of the antifibrillatory effects of carvedilol. | 2001 Jan |
|
| Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. | 2001 Jan |
|
| [Comprehensive anti-adrenergic therapy. It can save the weak heart]. | 2001 Jan 25 |
|
| [Effects of carvedilol in rats with induced chronic kidney failure]. | 2001 Jan-Feb |
|
| Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. | 2001 Jan-Feb |
|
| Stereoselective effects of (R)- and (S)-carvedilol in humans. | 2001 Jul |
|
| Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. | 2001 Jul 15 |
|
| Using isoproterenol stress echocardiography to predict the response to carvedilol in patients with dilated cardiomyopathy. | 2001 Jun |
|
| Beta-blockers to reduce mortality in patients with systolic dysfunction: a meta-analysis. | 2001 Jun |
|
| Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. | 2001 Jun |
|
| Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. | 2001 Jun |
|
| A cost-effectiveness analysis of bisoprolol for heart failure. | 2001 Jun |
|
| Differing beta-blocking effects of carvedilol and metoprolol. | 2001 Jun |
|
| Influence of carvedilol on the benefits of physical training in patients with moderate chronic heart failure. | 2001 Jun |
|
| Carvedilol increases plasma vascular endothelial growth factor (VEGF) in patients with chronic heart failure. | 2001 Jun |
|
| Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. | 2001 Jun |
|
| Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. | 2001 Jun |
|
| Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. | 2001 Jun 1 |
|
| Protective effect of carvedilol on chenodeoxycholate induction of the permeability transition pore. | 2001 Jun 1 |
|
| Beta-blocker trials seem to be in conflict. | 2001 Jun 12 |
|
| Beta-blockade in chronic heart failure. | 2001 Jun 12 |
|
| Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. | 2001 Jun 15 |
|
| Nebivolol, carvedilol and metoprolol do not influence cardiac Ca(2+) sensitivity. | 2001 Jun 22 |
|
| Random research. | 2001 Jun 26 |
|
| [Adrenergic beta inhibitors in heart insufficiency: which and when?]. | 2001 Mar |
|
| Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis. | 2001 Mar |
|
| Extracellular matrix proteins in cardiac fibroblasts derived from rat hearts with chronic pressure overload: effects of beta-receptor blockade. | 2001 Mar |
|
| Benefits of beta-blockers in heart failure: a class specific effect? | 2001 May |
|
| Does intention-to-treat analysis answer all questions in long-term mortality trials? Considerations on the basis of the ANZ trial. | 2001 May |
|
| Mechanisms of carvedilol action in human congestive heart failure. | 2001 May |
|
| Overview of the results of recent beta blocker trials. | 2001 May |
|
| Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. | 2001 May |
|
| Carvedilol versus other beta-blockers in heart failure. | 2001 May |
|
| Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. | 2001 May 22 |
|
| Racial differences in the response to drugs--pointers to genetic differences. | 2001 May 3 |
|
| Expanding indications for beta-blockers in heart failure. | 2001 May 31 |
|
| Effect of carvedilol on survival in severe chronic heart failure. | 2001 May 31 |
|
| Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence. | 2001 May 5 |
|
| Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. | 2001 May 5 |
|
| Current role of beta-adrenergic blockers in the management of chronic heart failure. | 2001 May 7 |
|
| Economic impact of beta blockade in heart failure. | 2001 May 7 |
Sample Use Guides
Take with food. Individualize dosage and monitor during up-titration.• Heart failure: Start at 3.125 mg twice daily and increase to 6.25, 12.5, and then 25 mg twice daily over intervals of at least 2 weeks. Maintain lower doses if higher doses are not tolerated.• Left ventricular dysfunction following myocardial infarction: Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily afterintervals of 3 to 10 days. A lower starting dose or slower titration may be used.• Hypertension: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg then 25 mg twice daily over intervals of 1 to 2 weeks.
Route of Administration:
Oral
Compared with the PDGF-stimulated control, DNA synthesis decreased significantly to 60.3% +/- 10.4% and 18.3% +/- 5.9% in the presence of 1 and 10 microM of carvedilol, respectively (P < 0.05, each). Carvedilol significantly inhibited the activity of VSMCs stimulated by ET-1 and ANG-II. The IC50 of carvedilol was 1-10 microM. CsA only inhibited VSMCs significantly in the PDGF-stimulated subgroup. The addition of CsA in the presence of carvedilol did not affect the inhibitory activity of carvedilol. The pattern of inhibition in the combined group was uniform and similar to that of the carvedilol alone group, regardless of the stimulator used.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:38:20 GMT 2023
by
admin
on
Sat Dec 16 07:38:20 GMT 2023
|
| Record UNII |
15DX7Y16JB
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
374779-45-0
Created by
admin on Sat Dec 16 07:38:20 GMT 2023 , Edited by admin on Sat Dec 16 07:38:20 GMT 2023
|
PRIMARY | |||
|
9827459
Created by
admin on Sat Dec 16 07:38:20 GMT 2023 , Edited by admin on Sat Dec 16 07:38:20 GMT 2023
|
PRIMARY | |||
|
15DX7Y16JB
Created by
admin on Sat Dec 16 07:38:20 GMT 2023 , Edited by admin on Sat Dec 16 07:38:20 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
